Crizanlizumab (anti-P-selectin mAb) for vaso-occlusive crisis prevention in HBB p.Glu7Val sickle cell disease

For HBB c.20A>T (p.Glu7Val), the causal variant of sickle cell disease, crizanlizumab (Adakveo, Novartis) is a humanized anti-P-selectin monoclonal antibody that reduces vaso-occlusive crises (VOCs) by blocking the adhesion cascade that drives sickle cell vaso-occlusion. P-selectin is upregulated on activated endothelium and platelets in SCD, mediating adhesion of sickled red blood cells, neutrophils, and platelets to the vascular wall — the initiating event in VOC. Crizanlizumab received FDA accelerated approval in November 2019 based on the Phase 2 SUSTAIN trial (PMID: 27959701), which showed 45% reduction in annual VOC rate (1.63 vs 2.98 events/year). Unlike curative approaches (Casgevy, Zynteglo, HSCT), crizanlizumab is a disease-modifying therapy that addresses the downstream vascular pathology without correcting the underlying hemoglobin defect.

The SUSTAIN Phase 2 trial (Ataga et al., 2017, PMID: 27959701, NEJM) randomized 198 SCD patients (HbSS and HbS-beta0 thalassemia) to crizanlizumab 5 mg/kg, 2.5 mg/kg, or placebo IV every 4 weeks. The 5 mg/kg arm showed 45.3% reduction in median annual VOC rate (p=0.01), with 35.8% of patients experiencing zero VOCs during the study. Time to first VOC was significantly delayed (4.07 vs 1.38 months). The confirmatory Phase 3 STAND trial, however, did not meet its primary endpoint of annualized rate of VOCs leading to healthcare visits, and Novartis voluntarily withdrew crizanlizumab from the US market in 2024 — though it remains available in some regions. The mechanism is well-validated: P-selectin blockade disrupts the multicellular adhesion cascade (endothelium-neutrophil-RBC-platelet aggregates) that is central to vaso-occlusion. The anti-adhesion approach is complementary to HbF induction (hydroxyurea), anti-sickling therapies (voxelotor), and curative gene therapy/editing.

The Phase 3 STAND trial failure and subsequent US market withdrawal significantly undermine the clinical evidence base for crizanlizumab. While SUSTAIN showed benefit, the inability to replicate this in STAND raises questions about the magnitude and consistency of the therapeutic effect. Crizanlizumab addresses only one pathological mechanism (adhesion) in a multifactorial disease — sickling itself, hemolysis, inflammation, and vasculopathy all contribute to SCD morbidity. Monthly IV infusions are required indefinitely, creating access and adherence challenges, particularly in low-resource settings where SCD prevalence is highest (sub-Saharan Africa, India). In the context of now-available curative options — Casgevy (CRISPR BCL11A editing) and Zynteglo (lentiviral beta-globin gene addition), both FDA-approved in 2023 — the role of antibody therapy is increasingly as a bridge or alternative for patients who are not candidates for or cannot access curative treatment. Cost (approximately $100,000/year) and the need for IV administration limit global applicability.